We believe connections and community are prerequisites for success.
We believe the physical layer of the world is in play.
We like hard problems at the earliest stages that impact the world in positive ways.
Given our technical background, we are unafraid to venture places other funds won’t.
We believe in never being satisfied while also being humble.
About KdT Ventures
Here at KdT Ventures, we believe, thanks to massive advances in computation and the life sciences, that the physical layer of the world is in play. What we once believed as Science Fiction is now becoming a reality as we build cellular circuits and logic gates, direct science using robots and computers, and edit genes in vivo. We aren’t afraid of the future here at KdT, we embrace it and the entrepreneurs that create it.
Managing Partner and Founder
Cain McClary, MD
Cain McClary, MD is the founder and Managing Partner of KdT Ventures. A native of Nashville, TN, Cain received his Sc.B. in Biochemistry and Molecular Biology from Brown University in 2007. During his undergraduate studies, Cain studied proteins involved in the development of appendages, both in the labs of Dr. Kristi Wharton at Brown University and Dr. Fred Kaplan at the University of Pennsylvania.
Following Brown, Cain went on to receive his medical degree from Tulane University School of Medicine in 2012. During medical school, Cain also spent a year at the National Institutes of Health (NIH) as part of the prestigious Howard Hughes Medical Institute “Cloister” Fellowship, where he studied the role of non-coding RNA in cancer at the National Cancer Institute (NCI) in the lab of Dr. Curtis Harris.
Immediately following medical school, Dr. McClary underwent residency training in anatomic pathology at Stanford University, where during his final year, he was named Chief Resident. While in residency, Dr. McClary discovered  a genetic mutation in a rare jaw tumor, ameloblastoma. This discovery subsequently led to a successful phase IV clinical trial of BRAF inhibitors in ameloblastoma, a condition where previously surgery was the only option. Due to this success, Dr. McClary was appointed as Assistant Professor in the Department of Pathology at Stanford University, becoming the youngest person on faculty in pathology at the time. He has won several notable awards, spoken at universities and national conferences, and published more than 10 peer reviewed articles.
Most recently, prior to the founding of KdT Ventures, Cain was the lead pathologist, analytics and data science clinical thought leader, and staff physician for Grand Rounds, a San Francisco, CA based digital health company focused on objectively quantifying physician quality for large self-insured employers. During his time at Grand Rounds, Cain developed the pathology program to support over 2 million lives, negotiated several high impact academic and employer relationships, and helped to lead the training team for all onboarding physicians.
Over the past 10 years, Cain has been at the forefront of the intersection between technology and science/medicine. In addition to personal investments in this space with outsized returns, including companies like Zymergen, Firefly Bioworks (Acquired by AbCam), Concert Genetics, and PathAI, Cain has been an active advisor to both companies and institutional investors (i.e. Lux Capital, Andreessen Horowitz, 8VC, Innovation Endeavors, NueCura Partners, Cleargenes, HealthSpek, etc…), with contributions ranging from scientific thesis development all the way to monetization of product/company. Additionally, Cain is involved in entrepreneurship and finance advisory at both the local (Mentor at the Economic Development Center of Asheville/Venture Asheville) and national levels (Finance Committee Member of the US and Canadian Academy of Pathology) as well as on the faculty at the Tulane University School of Medicine.
Phil Grayeski, an MD-PhD Candidate at UNC-Chapel Hill, is a Venture Associate. Originally from the US Pharma Capital, New Jersey, Phil headed down south to the University of Georgia (UGA) as a Foundation Fellow and received his B.S. in Chemistry and Genetics. During his undergraduate, Phil received top university awards in genetics and in chemistry as well as the national Goldwater Scholarship as a result of his work across microbial genetic engineering, gene therapy, and nanoparticle development.
Following UGA, Phil received his M.Phil in Bioscience Enterprise (MBE) at the University of Cambridge. While there, Phil worked with Lone Pine Capital (Greenwich, CT), assisted a wound-healing spin-out with clinical development strategy, and led a venture purifying acidic whey, a byproduct from greek yogurt manufacturing using novel filtration membrane technology. The culmination of his work received recognition at several international business competitions, and he was awarded the university-wide Young Life Science Entrepreneur of the Year award.
Phil is currently in the latter portion of his PhD in the MD-PhD program at the University of North Carolina – Chapel Hill (UNC), where he studies messenger RNA (mRNA) structure’s role in disease, particularly focused on its impact on protein translation. To date, his research is helping inform broad-questions around the “druggability” of mRNA and defining entirely new structural motifs that may be perturbed by small molecules. For this work, Phil was awarded the prestigious Ruth L. Kirschstein F30 Fellowship by the NHLBI.
Most notably, Phil has been actively engaged in the surrounding biotech community while completing school. He has been instrumental in spinning out two biotechnology companies while completing his first two years of medical school. The first company, Stride Bio, was founded with Aravind Asokan in November 2015. Stride is a gene therapy company designing next-generation capsids capable of evading a patient’s pre-existing immune system. The second company, Ribometrix, was founded with Kevin Weeks in April 2016, and represents a broad-based platform designing small molecule drugs against functional RNA structures. Since each of their respective foundings, StrideBio has raised over $15M (including participation by Takeda Ventures) while Ribometrix has raised over $30M (with participation by Merck Ventures, Abbvie, Amgen, and Illumina). Currently, Phil is incubating his third company.
Head of Operations
Ally Gudeman serves as the Head of Operations at KdT Ventures. Joining the KdT team in January of 2018, she comes with a background in administration, management, and company operations at the professional level. While a native of southern California, Ally and her husband currently reside in Princeton, New Jersey. Ally is a self-motivated and positive team member who is passionate about practicing organizational systems that empower and support KdT’s values and mission.